JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis

  • 0Sheila Sherlock Liver Centre and UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK.
Hepatology Communications +

|

July 5, 2024

|

July 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Novel noninvasive markers, propeptide of type III collagen (Pro-C3) and enhanced liver fibrosis (ELF) score, can accurately diagnose fibrosis stage and predict disease progression in primary sclerosing cholangitis (PSC). These markers show clinical utility for staging and prognosis.

Area Of Science

  • Hepatology
  • Biomarker Discovery
  • Fibrosis Research

Background

  • Primary sclerosing cholangitis (PSC) requires novel noninvasive predictors for disease severity and prognosis.
  • Current diagnostic methods for PSC fibrosis staging and progression are limited.

Purpose Of The Study

  • To evaluate extracellular matrix remodeling markers for diagnosing fibrosis stage in PSC.
  • To assess the predictive ability of these markers for PSC-related fibrosis progression and clinical events.

Main Methods

  • Assessed liver histology and serum markers including propeptide of type III collagen (Pro-C3), collagen degradation products, and enhanced liver fibrosis (ELF) score in 234 PSC patients.
  • Evaluated diagnostic performance for advanced fibrosis and cirrhosis using logistic regression and AUROC.
  • Assessed prognostic performance for PSC-related clinical events and fibrosis progression.

Main Results

  • 51% of patients had advanced fibrosis and 11% had cirrhosis at baseline.
  • Pro-C3 and ELF score demonstrated moderate diagnostic ability for advanced fibrosis and cirrhosis (AUROC 0.73-0.81).
  • Pro-C3, ELF score, and type III procollagen moderately predicted PSC-related clinical events (AUROC 0.70-0.71) and fibrosis progression.

Conclusions

  • Pro-C3 and ELF score correlate with fibrosis stage in PSC.
  • These markers effectively discriminate advanced fibrosis and cirrhosis, and predict clinical events and fibrosis progression.
  • Pro-C3 and ELF score hold significant clinical utility for staging and prognostication in PSC.